Armed with a $100 million second-round financing, CAMP4 Therapeutics is preparing to start the first clinical trial of a drug targeting regulatory RNA (regRNA) molecules that can be used to
The buoyant financing environment for digital health companies that took off during the pandemic looks like it has come to an end, according to new figures from market watcher Rock Health.<
Blueprint Medicines has taken an unusual route to raising cash for its R&D pipeline – selling off some of the royalties from its already-approved medicines in return for a cash injectio
Insilico Medicine has raised $60 million in fourth-round financing that will help to fund the advancement of more drugs towards the clinical testing stage.
SwanBio Therapeutics has raised $56 million in a second-round financing that will be used to advance its lead gene therapy candidate for adrenomyeloneuropathy (AMN) into clinical testing la